Roche stepped up its acquisition activity in 2014 with the goal of broadening its pharmaceutical base and augmenting its diagnostics business with new gene sequencing technologies. Sales of oncology drugs were a key growth driver, but at least one late-stage cancer trial failed to show statistical superiority.
